Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

The impact of APOE status on relationship of biomarkers of vascular risk and systemic inflammation to neuropsychiatric symptoms in Alzheimer's disease.

Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE.

J Alzheimers Dis. 2014;40(4):887-96. doi: 10.3233/JAD-131724.

PMID:
24577461
2.

Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease.

Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Winter AS, Singh M, O'Bryant SE.

J Alzheimers Dis. 2013;35(2):363-71. doi: 10.3233/JAD-122359.

3.

Total cholesterol and neuropsychiatric symptoms in Alzheimer's disease: the impact of total cholesterol level and gender.

Hall JR, Wiechmann AR, Johnson LA, Edwards M, Barber RC, Cunningham R, Singh M, O'Bryant SE.

Dement Geriatr Cogn Disord. 2014;38(5-6):300-9. doi: 10.1159/000361043. Epub 2014 Jul 4.

4.

The APOE polymorphism in Alzheimer's disease patients with neuropsychiatric symptoms and syndromes.

D'Onofrio G, Panza F, Seripa D, Sancarlo D, Paris F, Cascavilla L, Urbano M, Gravina C, Fontana A, Solfrizzi V, Pellegrini F, Pilotto A.

Int J Geriatr Psychiatry. 2011 Oct;26(10):1062-70. doi: 10.1002/gps.2644. Epub 2010 Oct 29.

PMID:
21905100
5.

Butyrylcholinesterase K and apolipoprotein ε4 affect cortical thickness and neuropsychiatric symptoms in Alzheimer's disease.

Yoo HB, Lee HW, Shin S, Park SW, Choi JS, Jung HY, Cha J, Lee JM, Lee JY.

Curr Alzheimer Res. 2014 Feb;11(2):137-44.

PMID:
24479631
6.

Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.

Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; Alzheimer’s Disease Neuroimaging Initiative.

JAMA Psychiatry. 2014 Oct;71(10):1183-91. doi: 10.1001/jamapsychiatry.2014.1060.

PMID:
25162367
7.

A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI.

O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, Graff-Radford N, Doody R, Diaz-Arrastia R; Texas Alzheimer's Research & Care Consortium; Alzheimer's Disease Neuroimaging Initiative.

PLoS One. 2011;6(12):e28092. doi: 10.1371/journal.pone.0028092. Epub 2011 Dec 7.

8.

Increased Alzheimer's disease neuropathology is associated with type 2 diabetes and ApoE ε.4 carrier status.

Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, Walker DG, Lue L, Adem A, Sabbagh MN.

Curr Alzheimer Res. 2013 Jul;10(6):654-9.

9.

Sex Differences in Neuropsychiatric Symptoms of Alzheimer's Disease: The Modifying Effect of Apolipoprotein E ε4 Status.

Xing Y, Tang Y, Jia J.

Behav Neurol. 2015;2015:275256. doi: 10.1155/2015/275256. Epub 2015 Oct 11.

10.

Apolipoprotein E genotypes and neuropsychiatric symptoms and syndromes in late-onset Alzheimer's disease.

Panza F, Frisardi V, Seripa D, D'Onofrio G, Santamato A, Masullo C, Logroscino G, Solfrizzi V, Pilotto A.

Ageing Res Rev. 2012 Jan;11(1):87-103. doi: 10.1016/j.arr.2011.06.005. Epub 2011 Jul 7. Review.

PMID:
21763789
11.

Serum total cholesterol, apolipoprotein E epsilon 4 allele, and Alzheimer's disease.

Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, Kivinen P, Tuomilehto J, Nissinen A.

Neuroepidemiology. 1998;17(1):14-20.

PMID:
9549720
12.

Apolipoprotein E ε4 status modifies the effects of sex hormones on neuropsychiatric symptoms of Alzheimer's disease.

Xing Y, Qin W, Li F, Jia XF, Jia J.

Dement Geriatr Cogn Disord. 2012;33(1):35-42. doi: 10.1159/000336600. Epub 2012 Mar 2.

PMID:
22398564
13.

Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba.

Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, Gureje O, Dickens J, Evans R, Smith-Gamble V, Unverzagt FW, Shen J, Hendrie H.

Neurology. 2006 Jan 24;66(2):223-7.

14.

Identification of peripheral inflammatory markers between normal control and Alzheimer's disease.

Kim SM, Song J, Kim S, Han C, Park MH, Koh Y, Jo SA, Kim YY.

BMC Neurol. 2011 May 12;11:51. doi: 10.1186/1471-2377-11-51.

15.

Lack of reliable evidence for a distinctive ε4-related cognitive phenotype that is independent from clinical diagnostic status: findings from the Australian Imaging, Biomarkers and Lifestyle Study.

Foster JK, Albrecht MA, Savage G, Lautenschlager NT, Ellis KA, Maruff P, Szoeke C, Taddei K, Martins R, Masters CL, Ames D; AIBL Research Group.

Brain. 2013 Jul;136(Pt 7):2201-16. doi: 10.1093/brain/awt127. Epub 2013 Jun 3.

16.
17.

An increased neutrophil-lymphocyte ratio in Alzheimer's disease is a function of age and is weakly correlated with neocortical amyloid accumulation.

Rembach A, Watt AD, Wilson WJ, Rainey-Smith S, Ellis KA, Rowe CC, Villemagne VL, Macaulay SL, Bush AI, Martins RN, Ames D, Masters CL, Doecke JD; AIBL Research Group.

J Neuroimmunol. 2014 Aug 15;273(1-2):65-71. doi: 10.1016/j.jneuroim.2014.05.005. Epub 2014 May 20.

PMID:
24907904
18.

Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers.

González C, Martín T, Cacho J, Breñas MT, Arroyo T, García-Berrocal B, Navajo JA, González-Buitrago JM.

Eur J Clin Invest. 1999 Jul;29(7):637-42.

PMID:
10411671
19.

Association between apolipoprotein E epsilon4 allele and apathy in probable Alzheimer's disease.

Monastero R, Mariani E, Camarda C, Ingegni T, Averna MR, Senin U, Camarda R, Mecocci P.

Acta Psychiatr Scand. 2006 Jan;113(1):59-63. Erratum in: Acta Psychiatr Scand. 2005 Dec;112(6):481.

PMID:
16390371
Items per page

Supplemental Content

Write to the Help Desk